Gain Therapeutics, Inc. (NasdaqGM: GANX)
Health Care · Biotechnology · US
$1.62
-5.56% today · -23.0% 1Y
Gain Therapeutics, Inc. (NasdaqGM: GANX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $74.63M and employs 21 people.
Over the last twelve months the share price has lost 23.0%, trading between 1.53 and 4.34.
Tweenvest scores Gain Therapeutics, Inc. across four factors: quality 44/100, value 67/100. Its strongest factor is value.
GANX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $74.63M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.51
- Dividend yield
- —
- Beta (5Y)
- 0.19
- 52-week high
- $4.34
- 52-week low
- $1.53
- Avg volume (3M)
- —
- Shares outstanding
- 43.64M
- Employees
- 21
- Next earnings
- —
About Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurological ailments. It employs its unique Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to pinpoint specific allosteric sites on malformed proteins. Subsequently, Gain Therapeutics identifies proprietary small molecules designed to bind to these locations, thereby restoring correct protein conformation and alleviating the disease. Their current development pipeline includes several structurally targeted allosteric regulator candidates aimed at combating a range of diseases, such as Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1. Established in 2017, the company is headquartered in Bethesda, Maryland.
- ISIN
- US36269B1052
- Founded
- 2017
- Listed since
- Mar 19, 2021
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Sensorion SAENXTPA: ALSEN | $76.66M | €5.90 | -10.74% |
| CORESTEMCHEMON Inc.KOSDAQ: A166480 | $76.25M | ₩2,315.00 | +8.94% |
| MedPacto, Inc.KOSDAQ: A235980 | $75.59M | ₩2,970.00 | +5.88% |
| OS Therapies IncorporatedNYSEAM: OSTX | $74.72M | $1.62 | 0.00% |
| Gwo Xi Stem Cell Applied Technology Co. , LtdTPEX: 6704 | $74.40M | NT$24.70 | +12.53% |
| Vaxcell-Bio Therapeutics Co., Ltd.KOSDAQ: A323990 | $74.00M | ₩4,285.00 | +1.78% |
| MAIA Biotechnology, Inc.NYSEAM: MAIA | $72.38M | $1.15 | -3.36% |
| iBio, Inc.NasdaqCM: IBIO | $72.35M | $0.92 | -18.22% |
Figures last refreshed Oct 4, 2026.